Clay Siegall has been working in the biotech industry for many years, and he helped to co-found the company, Seattle Genetics. He helped to put the company together because of his strong interest in medicine and his belief in the power of technology. It was during his days at the University of Maryland that he found he had an interest in cancer while he was working on a Zoology degree. When he saw how bad chemotherapy effected a family member who had cancer, he realized he wanted to do something about the way that cancer was treated. Once he realized he could tie together his passion for helping people who had cancer with a business model that could help him to earn a steady living, he began to work on the beginnings of Seattle Genetics. He attributes the early success of the company with to the dynamic sales team behind it that was able to get it off of the ground even though the product was good enough to sell itself.
Clay Siegall is the co-founder, President, Chief Executive Officer, and Chairman of the Board for Seattle Genetics. He brings with him a wealth of knowledge as a trained scientist who focused in on therapies for cancer, and he also has a tremendous passion for being a positive part of patients’ lives. Siegall was the reason why the company was able to get FDA approval for for ADCETRIS, which was its original ADC product. ADCETRIS has now become a worldwide brand through a partnership with Takeda Pharmaceutical Company.
Clay Siegall is also a large part of the reason why Seattle Genetic’s ADC technology has been able to enter a spread of strategic licenses. They have worked with Pfizer, GlaxoSmithKline, Genentech, and AbbVie and have produced over $350 million so far. Siegall also guided Seattle Genetics with its efforts to raise money and has helped the company obtain private and public financing to the tune of over $1.2 billion. He attended the University of Maryland where he earned a Bachelor’s Degree of Science in Zoology and went on to study at George Washington University where he received his PhD in Genetics.